Just got my Medicines offer...

Quote












Anonymous said:
You might not want to spend that $150 right away. I have been talking to a very, very large health system in my area. They have already compared dalba and orita and orita is dog shit! Just compare the labels. It's not even close. This will be the case all over the country and the Med Co. will be all over your ass in about 6 months when it is rejected by most P&T's. It's already happening. Have fun.
Click to expand...


Hey dipshit!!! Who gives a fuck??? I'd rather get a $150k base (+60k at plan bonus) and have a "hard to sell" product rather than a 100-120k base (+ 40 K at plan bonus) and have 5 great drugs with a shitty unatainalble bonus structure. Even if the bouns was a wash (which I doubt it is), that's 30 to 50k more and one product to worry about vs.5!!! Get your head outta your ass you moron!!! We used to make 40-80K on one product and now were making 10-25k on 4. WTF?!?!?!?!
 






Interesting, MDCO telling analyst's Orbativ will be a big drug. Can't imagine what the revenue expectations will be. I am sure they will be very low so you can easily make the big bucks.
 












The timing may be right for a takeover of Cubist Pharmaceuticals Inc. (CBST)

The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020 to combat bacterial infections that have become resistant to older therapies because of decades of overuse.

Cubist may receive takeover offers based on the prospects for those remedies and could get sold for about 50 percent more than its current price, Cowen Group Inc. said. It already has one blockbuster drug on the market, and analysts estimate its revenue will double to almost $2 billion by 2018. Pfizer Inc. (PFE) could fold Cubist’s antibiotics sales force into its acute-care division, while new legislative efforts to revive the antibiotic market also could draw Eli Lilly (LLY) & Co. or Johnson & Johnson (JNJ) to the bidding table, according to Robert W. Baird & Co.

Cubist “would be pretty accretive to any company who would be looking to buy them,” Brian Skorney, a New York-based analyst at Baird, said in a phone interview. “They have a drug that’s selling $1 billion a year in the U.S. That’s always an attractive asset.”

If the new drugs “are as successful as management’s contention is, the valuation would see a significant step up and any M&A premium would see a similar step up,” he said.

Unmet Need
Julie DiCarlo, a spokeswoman for Lexington, Massachusetts-based Cubist, declined to comment. Representatives for Indianapolis-based Lilly, J&J and New York-based Pfizer declined to comment.

Drug companies had largely abandoned antibiotics to focus on more profitable chronic illnesses, such as diabetes and heart disease. Now that traditional antibiotics are becoming ineffective, there’s growing unmet demand. It means that common infections and minor injuries could end up being deadly, according to the World Health Organization.

The U.S. Centers for Disease Control and Prevention said antibiotic resistance is killing at least 23,000 Americans a year, making it “one of our most serious health threats.”

Incentive Program
President Barack Obama enacted the Generating Antibiotic Incentives Now, or GAIN Act, in 2012 to encourage drugmakers to invest in new antibiotics by lengthening the time they get to sell the treatment exclusively before facing competition from cheaper generic versions.

The GAIN Act may entice companies that don’t have an existing antibiotics business to make bids for Cubist to enter the market, said David Krempa, a Chicago-based analyst at Morningstar Inc. It might be enough to get Lilly or New Brunswick, New Jersey-based J&J “back in the game,” Skorney of Baird said.

“It’s not like it’s a small company where the only people it would make sense for it to be bought by are people that already have the presence there and can buy and cut out the sales force,” Krempa said in a phone interview. “Cubist is big enough that if someone were looking to get into that market that could be one way to get in.”

Cubist would also be a cheap takeover candidate, making a deal even more compelling, he said.

The drug developer was valued last week at 2.4 times analysts’ average revenue estimate for 2018. That’s a lower valuation than 86 percent of U.S. pharmaceutical and biotechnology companies larger than $1 billion, according to data compiled by Bloomberg.

Shares of Cubist climbed 0.7 percent to $63.85 at 9:37 a.m. New York time today.

Less Risk
Cubist’s Cubicin, a daily injection to treat Methicillin-resistant Staphylococcus Aureus, or MRSA, is what the pharmaceutical industry calls a blockbuster drug because it generates more than $1 billion in annual revenue. That makes Cubist a less risky target than a biotechnology company that doesn’t yet have any approved or marketed medicines, said Alan Carr, an analyst at Needham & Co.

“Acquirers have tended to be risk-averse and have looked for later stage assets when they’re acquiring something,” Carr said in a phone interview. “They’d rather pay more for a de-risked asset rather than invest in something early stage that has a lot of risk embedded in it.”

Pfizer Synergies
For companies that still have at least a small sales team dedicated to antibiotics like Cubicin, Cubist would be a relatively easy company to acquire, according to Irina Rivkind, a New York-based analyst with Cantor Fitzgerald.

Pfizer’s best-selling antibiotic -- Zyvox, for MRSA -- generated $1.35 billion of sales last year and will begin facing generic competition in the second quarter of 2015. An easy way for Pfizer to maintain its anti-infective revenue would be to acquire a company such as Cubist, Rivkind said in an e-mail.

“It can generate cost synergies by acquiring Cubist and stripping out its sales force and research expenditures,” she said.

There have been a flurry of mergers and acquisitions in the health-care industry this year, driven by growth-hungry acquirers seeking to take advantage of low interest rates and also reduce their taxes. The record $320 billion of transactions through last week is already double the volume for all of last year, according to data compiled by Bloomberg.

A drugmaker might pay $95 a share for Cubist, representing a 50 percent premium to last week’s closing price, according to the average of three analysts’ estimates. That would value the company at more than $7 billion. Skorney said that could be a problem for Cubist’s management, who may value the company’s antibiotic pipeline much higher.

New Drugs
Cubist has applied for U.S. Food and Drug Administration approval for ceftolozane/tazobactam, an antibiotic for complicated urinary tract infections. If the drug is approved, which could happen as early as December, a buyer that has both U.S. and international hospital-based sales teams would be drawn to the asset, Ken Cacciatore, a New York-based analyst at Cowen, wrote in a July 23 report.

On the other hand, the low profit margins for antibiotics may make Cubist less appealing, Skorney said. Cubist earned less than a penny of profit on each dollar of sales in the past 12 months, versus the 6-cent average for its closest peers, data compiled by Bloomberg show.

“You really have very little pricing power and there’s so many generic options available to treat bacterial infections that the products become very, very niche,” Skorney said.

That may be changing. Biotechnology companies are beginning to demand better prices for their antibiotics, and the growing need for new medicines may position Cubist to profit off this improved pricing power, Morningstar’s Krempa said.

Antibiotics “have life-saving power and yet people are only paying hundreds or a couple thousand dollars for them,” Krempa said. “You should be able to increase prices consistently for a long period of time.”
 






It will only take 1 serious drug interaction and/or hypersensitivity event to put a bullet in this drug. By the way does anybody know were this drug is elimnated? Only 5% and 1% are excreted in the urine and feces? Heard it accumulates in the liver. By the way if you gave a patient this drug todday it would still be in their body in November!!!
 


















dk...I'm torn. Been here a long time but the opportunities seem pretty good...Sure, Oritavancin may be banned from most hospitals in-patient-wise but the outpatient potential seems promising and you guys are right. It's all going to be HOW THEY PRICE IT....But in saying that, it's going to be a HUGE shift in the continuum in the way ID's use antibiotics. They are use to once-day/twice a day products with relatively short infusion time. However, One dose, 3 hours in a chair might have some attractiveness factor depending on how reimbursement will work. There are OTHER examples of infused products that have rather long infusion times that docs get reimbursed for just fine and they make good money on them. Having to come back everyday for 10 days on dapto for skin infections to get poked to me sounds more cumbersome than a one, 3 hour infusion. Maybe not for EVERYBODY but time is money for a lot of folks and perhaps that one dose might be attractive to some, not all...Will it take over the Vancomycin market ? Probably not. Hell, Cubicin, didn't take over the Vancomycin market and we're all fighting for market share. Sivextro hasn't really launched as well as I had hoped so not sure where Oritavancin will fit. It's going to be niched but not sure where yet. Im more interested in their gram-negative coming in 2016 (maybe) with KPC coverage. THAT one sounds more appealing to me. So, if I could buy some time with sales in Oritavancin and just hang tight, this gram negative could potentially be the blockbuster everyone is looking for. Durata doesn't appeal to me at all. Too risky with a one hit wonder that is really crashing and burning as we speak...At least with the Medicine's company, if you are deciding which one to go to, they have other products and seem to be cash heavy. That's important if you're looking to make a move.
 






Anonymous said:
dk...I'm torn. Been here a long time but the opportunities seem pretty good...Sure, Oritavancin may be banned from most hospitals in-patient-wise but the outpatient potential seems promising and you guys are right. It's all going to be HOW THEY PRICE IT....But in saying that, it's going to be a HUGE shift in the continuum in the way ID's use antibiotics. They are use to once-day/twice a day products with relatively short infusion time. However, One dose, 3 hours in a chair might have some attractiveness factor depending on how reimbursement will work. There are OTHER examples of infused products that have rather long infusion times that docs get reimbursed for just fine and they make good money on them. Having to come back everyday for 10 days on dapto for skin infections to get poked to me sounds more cumbersome than a one, 3 hour infusion. Maybe not for EVERYBODY but time is money for a lot of folks and perhaps that one dose might be attractive to some, not all...Will it take over the Vancomycin market ? Probably not. Hell, Cubicin, didn't take over the Vancomycin market and we're all fighting for market share. Sivextro hasn't really launched as well as I had hoped so not sure where Oritavancin will fit. It's going to be niched but not sure where yet. Im more interested in their gram-negative coming in 2016 (maybe) with KPC coverage. THAT one sounds more appealing to me. So, if I could buy some time with sales in Oritavancin and just hang tight, this gram negative could potentially be the blockbuster everyone is looking for. Durata doesn't appeal to me at all. Too risky with a one hit wonder that is really crashing and burning as we speak...At least with the Medicine's company, if you are deciding which one to go to, they have other products and seem to be cash heavy. That's important if you're looking to make a move.
Click to expand...

Cubist Gram negative will not be a block buster like you were told my friend ask your ID Docs who really are in the know. This drug will be over priced and niche like everything Cubist brings to the market. You will be doing more heaven lifting in Jan. 2015.
 






Anonymous said:
Cubist Gram negative will not be a block buster like you were told my friend ask your ID Docs who really are in the know. This drug will be over priced and niche like everything Cubist brings to the market. You will be doing more heaven lifting in Jan. 2015.
Click to expand...

Agreed but I'm liking the Carbavance product in the pipeline for The Medicines Company more than oritavancin. This particular carbapenem will have KPC coverage which C/T will not...again, probably niched but I'm more excited about that....Plus, it appears TMC had layoffs in 2013...idk...I'm not totally leaving yet, but Im not sure TMC is "IT" either...They both kinda suck...If TC wasn't around, I think I might stick around, but I'm looking like I'm sure a lot of peeps are...I figure if TMC can pay us a base of 150k then Cubist should up the anty and match it...They won't but you can't expect us to sell 5 drugs and make plan for all 5 and get that 40K...Like many have said, you might get 20k if you're lucky getting 2-3 products to plan
 






Anonymous said:
dk...I'm torn. Been here a long time but the opportunities seem pretty good...Sure, Oritavancin may be banned from most hospitals in-patient-wise but the outpatient potential seems promising and you guys are right. It's all going to be HOW THEY PRICE IT....But in saying that, it's going to be a HUGE shift in the continuum in the way ID's use antibiotics. They are use to once-day/twice a day products with relatively short infusion time. However, One dose, 3 hours in a chair might have some attractiveness factor depending on how reimbursement will work. There are OTHER examples of infused products that have rather long infusion times that docs get reimbursed for just fine and they make good money on them. Having to come back everyday for 10 days on dapto for skin infections to get poked to me sounds more cumbersome than a one, 3 hour infusion. Maybe not for EVERYBODY but time is money for a lot of folks and perhaps that one dose might be attractive to some, not all...Will it take over the Vancomycin market ? Probably not. Hell, Cubicin, didn't take over the Vancomycin market and we're all fighting for market share. Sivextro hasn't really launched as well as I had hoped so not sure where Oritavancin will fit. It's going to be niched but not sure where yet. Im more interested in their gram-negative coming in 2016 (maybe) with KPC coverage. THAT one sounds more appealing to me. So, if I could buy some time with sales in Oritavancin and just hang tight, this gram negative could potentially be the blockbuster everyone is looking for. Durata doesn't appeal to me at all. Too risky with a one hit wonder that is really crashing and burning as we speak...At least with the Medicine's company, if you are deciding which one to go to, they have other products and seem to be cash heavy. That's important if you're looking to make a move.
Click to expand...

You don't get it at all. Cubist was a one hit wonder back in 2003 just like Durata now. No one will reimburse for a 3 hour infusion when there is a 30 minute option that is 2 doses and will soon have flexibility in a single dose option. Orita should be discontinued in osteo and will never be more than a single dose drug. Dalba will get new indications and see use sky rocket in the 4, 6 8, week etc use indications. Most major health systems already looking at orita and they all say the same thing. 2nd line behind dalba at best. Good luck
 






Anonymous said:
You don't get it at all. Cubist was a one hit wonder back in 2003 just like Durata now. No one will reimburse for a 3 hour infusion when there is a 30 minute option that is 2 doses and will soon have flexibility in a single dose option. Orita should be discontinued in osteo and will never be more than a single dose drug. Dalba will get new indications and see use sky rocket in the 4, 6 8, week etc use indications. Most major health systems already looking at orita and they all say the same thing. 2nd line behind dalba at best. Good luck
Click to expand...

And you apparently don't get it. Durata doesn't have shit for a pipeline. There is NOTHING behind Dalba and if Dalba is so fantastic and Durata, then why so many of the Durata reps scrambling to go to TMC? Don't you think they might somehow know a little more than YOU do ? Durata is a "one-trick pony" with NOTHING to offer anybody...At least with TMC, they HAVE a pipeline and their antibiotic pipeline looks promising, certainly more promising than the C/T product that Cubist will probably overprice.

Good luck to you too
 






Anonymous said:
You don't get it at all. Cubist was a one hit wonder back in 2003 just like Durata now. No one will reimburse for a 3 hour infusion when there is a 30 minute option that is 2 doses and will soon have flexibility in a single dose option. Orita should be discontinued in osteo and will never be more than a single dose drug. Dalba will get new indications and see use sky rocket in the 4, 6 8, week etc use indications. Most major health systems already looking at orita and they all say the same thing. 2nd line behind dalba at best. Good luck
Click to expand...

If I went to TMC, it wouldn't be for the Oritavancin compound...It would be for their gram-negative due out in 2016. Read between the lines...
 






THIS IS FOR REAL: QUOTE=Anonymous;5184630]The timing may be right for a takeover of Cubist Pharmaceuticals Inc. (CBST)

The rising threat from drug-resistant germs and increasing calls from global health groups for more potent antibiotics is placing a premium on companies such as Cubist. The $4.8 billion drug developer is preparing to introduce four new medicines by 2020 to combat bacterial infections that have become resistant to older therapies because of decades of overuse.

Cubist may receive takeover offers based on the prospects for those remedies and could get sold for about 50 percent more than its current price, Cowen Group Inc. said. It already has one blockbuster drug on the market, and analysts estimate its revenue will double to almost $2 billion by 2018. Pfizer Inc. (PFE) could fold Cubist’s antibiotics sales force into its acute-care division, while new legislative efforts to revive the antibiotic market also could draw Eli Lilly (LLY) & Co. or Johnson & Johnson (JNJ) to the bidding table, according to Robert W. Baird & Co.

Cubist “would be pretty accretive to any company who would be looking to buy them,” Brian Skorney, a New York-based analyst at Baird, said in a phone interview. “They have a drug that’s selling $1 billion a year in the U.S. That’s always an attractive asset.”

If the new drugs “are as successful as management’s contention is, the valuation would see a significant step up and any M&A premium would see a similar step up,” he said.

Unmet Need
Julie DiCarlo, a spokeswoman for Lexington, Massachusetts-based Cubist, declined to comment. Representatives for Indianapolis-based Lilly, J&J and New York-based Pfizer declined to comment.

Drug companies had largely abandoned antibiotics to focus on more profitable chronic illnesses, such as diabetes and heart disease. Now that traditional antibiotics are becoming ineffective, there’s growing unmet demand. It means that common infections and minor injuries could end up being deadly, according to the World Health Organization.

The U.S. Centers for Disease Control and Prevention said antibiotic resistance is killing at least 23,000 Americans a year, making it “one of our most serious health threats.”

Incentive Program
President Barack Obama enacted the Generating Antibiotic Incentives Now, or GAIN Act, in 2012 to encourage drugmakers to invest in new antibiotics by lengthening the time they get to sell the treatment exclusively before facing competition from cheaper generic versions.

The GAIN Act may entice companies that don’t have an existing antibiotics business to make bids for Cubist to enter the market, said David Krempa, a Chicago-based analyst at Morningstar Inc. It might be enough to get Lilly or New Brunswick, New Jersey-based J&J “back in the game,” Skorney of Baird said.

“It’s not like it’s a small company where the only people it would make sense for it to be bought by are people that already have the presence there and can buy and cut out the sales force,” Krempa said in a phone interview. “Cubist is big enough that if someone were looking to get into that market that could be one way to get in.”

Cubist would also be a cheap takeover candidate, making a deal even more compelling, he said.

The drug developer was valued last week at 2.4 times analysts’ average revenue estimate for 2018. That’s a lower valuation than 86 percent of U.S. pharmaceutical and biotechnology companies larger than $1 billion, according to data compiled by Bloomberg.

Shares of Cubist climbed 0.7 percent to $63.85 at 9:37 a.m. New York time today.

Less Risk
Cubist’s Cubicin, a daily injection to treat Methicillin-resistant Staphylococcus Aureus, or MRSA, is what the pharmaceutical industry calls a blockbuster drug because it generates more than $1 billion in annual revenue. That makes Cubist a less risky target than a biotechnology company that doesn’t yet have any approved or marketed medicines, said Alan Carr, an analyst at Needham & Co.

“Acquirers have tended to be risk-averse and have looked for later stage assets when they’re acquiring something,” Carr said in a phone interview. “They’d rather pay more for a de-risked asset rather than invest in something early stage that has a lot of risk embedded in it.”

Pfizer Synergies
For companies that still have at least a small sales team dedicated to antibiotics like Cubicin, Cubist would be a relatively easy company to acquire, according to Irina Rivkind, a New York-based analyst with Cantor Fitzgerald.

Pfizer’s best-selling antibiotic -- Zyvox, for MRSA -- generated $1.35 billion of sales last year and will begin facing generic competition in the second quarter of 2015. An easy way for Pfizer to maintain its anti-infective revenue would be to acquire a company such as Cubist, Rivkind said in an e-mail.

“It can generate cost synergies by acquiring Cubist and stripping out its sales force and research expenditures,” she said.

There have been a flurry of mergers and acquisitions in the health-care industry this year, driven by growth-hungry acquirers seeking to take advantage of low interest rates and also reduce their taxes. The record $320 billion of transactions through last week is already double the volume for all of last year, according to data compiled by Bloomberg.

A drugmaker might pay $95 a share for Cubist, representing a 50 percent premium to last week’s closing price, according to the average of three analysts’ estimates. That would value the company at more than $7 billion. Skorney said that could be a problem for Cubist’s management, who may value the company’s antibiotic pipeline much higher.

New Drugs
Cubist has applied for U.S. Food and Drug Administration approval for ceftolozane/tazobactam, an antibiotic for complicated urinary tract infections. If the drug is approved, which could happen as early as December, a buyer that has both U.S. and international hospital-based sales teams would be drawn to the asset, Ken Cacciatore, a New York-based analyst at Cowen, wrote in a July 23 report.

On the other hand, the low profit margins for antibiotics may make Cubist less appealing, Skorney said. Cubist earned less than a penny of profit on each dollar of sales in the past 12 months, versus the 6-cent average for its closest peers, data compiled by Bloomberg show.

“You really have very little pricing power and there’s so many generic options available to treat bacterial infections that the products become very, very niche,” Skorney said.

That may be changing. Biotechnology companies are beginning to demand better prices for their antibiotics, and the growing need for new medicines may position Cubist to profit off this improved pricing power, Morningstar’s Krempa said.

Antibiotics “have life-saving power and yet people are only paying hundreds or a couple thousand dollars for them,” Krempa said. “You should be able to increase prices consistently for a long period of time.”[/QUOTE]
 






Anonymous said:
And you apparently don't get it. Durata doesn't have shit for a pipeline. There is NOTHING behind Dalba and if Dalba is so fantastic and Durata, then why so many of the Durata reps scrambling to go to TMC? Don't you think they might somehow know a little more than YOU do ? Durata is a "one-trick pony" with NOTHING to offer anybody...At least with TMC, they HAVE a pipeline and their antibiotic pipeline looks promising, certainly more promising than the C/T product that Cubist will probably overprice.

Good luck to you too
Click to expand...

Cubist had no pipeline in 2003 either. Cubist and Durata are the same place just 11 years apart.
 
























Top Bottom
Back
Quote